Antifungal resistance, metabolic routes as drug targets, and new antifungal agents: an overview about endemic dimorphic fungi
Nenhuma Miniatura disponível
Data
2017
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Diseases caused by fungi can occur in healthy people, but immunocompromised patients are the major risk group for invasive
fungal infections. Cases of fungal resistance and the difficulty of treatment make fungal infections a public health problem. This
review explores mechanisms used by fungi to promote fungal resistance, such as the mutation or overexpression of drug targets,
efflux and degradation systems, and pleiotropic drug responses. Alternative novel drug targets have been investigated; these
include metabolic routes used by fungi during infection, such as trehalose and amino acid metabolism and mitochondrial
proteins. An overview of new antifungal agents, including nanostructured antifungals, as well as of repositioning approaches is
discussed. Studies focusing on the development of vaccines against antifungal diseases have increased in recent years, as these
strategies can be applied in combination with antifungal therapy to prevent posttreatment sequelae. Studies focused on the
development of a pan-fungal vaccine and antifungal drugs can improve the treatment of immunocompromised patients and
reduce treatment costs.
Descrição
Palavras-chave
Citação
PARENTE-ROCHA, Juliana Alves et al. Antifungal resistance, metabolic routes as drug targets, and new antifungal agents: an overview about endemic dimorphic fungi. Mediators of Inflammation, New Jersey, v. 2017, e 9870679, 2017. DOI: 10.1155/2017/9870679. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485324/. Acesso em: 9 ago. 2024.